Evaluation of integrin αvβ3-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2)

Liang, Yiqian; Jia, Xi; Wang, Yuanbo; Liu, Yan; Yao, Xiaobao; Bai, Yang; Han, Peng; Chen, Si; Yang, Aimin; Gao, Rui

doi:10.1186/s40644-022-00511-0

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that, with growing serum Tg levels, both sensitivity and positive predictive value (PPV) remained high and even increased [51]. Additionally, it has been suggested that 99m Tc-3PRGD2 uptake can predict the disease progression after initial RAI therapy, in high risk DTC patients [52]. RGD peptides can be labeled also with positron emitting radionuclides for a PET/TC application.…”

Section: Future Diagnostic and Therapeutic Perspectivesmentioning

confidence: 99%

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Volpe,

Nappi,

Zampella

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine therapy is a cornerstone in DTC management, but sometimes it became useless when cancer cells develop refractoriness. Radioactive Iodine Refractory DTC (RAIR-DTC) is a condition defined by ATA 2015 guidelines when DTC cannot concentrate RAI ab initio or loses RAI uptake ability after the initial therapy. RAIR condition implies that RAI cannot reveal new met-astatic foci, so RAIR-DTC metabolic imaging needs new tracers. 18F-FDG PET/CT has been widely used, it has a demonstrated prognostic value, but 18F-FDG DTC avidity may remain low. FA-Pi, PSMA, SSTR tracers have been proposed as theragnostic agents in experimental settings and Arg-Gly-Asp (RGD) peptides in diagnostic trial field. Multi-targeted tyrosine kinase inhibitors are relatively new drugs approved in RAIR-DTC therapy. Despite the promising targeted setting, they relate to frequent adverse event onset. Sorafenib and trametinib have been included in re-differentiation protocols aimed to re-induce RAI accumulation in DTC cells. Results appeared promising, despite not excellent. Conclusions: RAIR-DTC yet represent a challenging nosological entity. There are still controversies on RAIR-DTC definition and post-RAI therapy evaluation with post-therapy whole body scan (PT-WBS) is the only validated criterion of response. The recent introduction of multiple diagnostic and therapeutic agents oblige physicians to pursue a multidisciplinary approach aiming to correct drug introduction and timing choice.

show abstract

Section: Future Diagnostic and Therapeutic Perspectivesmentioning

confidence: 99%

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Volpe,

Nappi,

Zampella

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The study observed that higher accumulations of 99mTc-3PRGD2 on scintigraphic images were associated with an increased risk of disease progression, including disease recurrence, metastasis, or worsening patient condition. Patients with greater accumulations of 99mTc-3PRGD2 exhibited poorer prognosis and shorter progression-free survival (65,66). The subsequent study conducted by Mautone et al aimed to investigate the correlation between the expression of integrin alpha 3 beta 1 receptors and patient outcomes in PTC.…”

Section: Integrinsmentioning

confidence: 99%

Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review

Buczyńska,

Kościuszko,

Krętowski

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, and angioinvasion, the invasion of blood vessels by cancer cells, is a crucial pathological feature associated with disease progression and poor prognosis. Thus, a comprehensive search of scientific databases was conducted to identify relevant studies investigating angioinvasion markers in PTC. The selected studies were reviewed and analyzed to assess the clinical significance and potential utility of these markers in predicting angioinvasion and guiding treatment decisions. Numerous studies have investigated various markers associated with angioinvasion in PTC, including oxidative stress, vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and other angiogenic factors. The results indicate that increased expression of these markers is correlated with the presence and extent of angioinvasion in PTC. Moreover, some studies suggest that these markers can serve as prognostic indicators and guide therapeutic strategies, such as selecting patients for more aggressive treatment approaches or targeted therapies. The findings from the reviewed literature highlight the potential clinical utility of angioinvasion markers in PTC. The identification and validation of reliable markers can aid in assessing the risk of angioinvasion, predicting disease progression, and optimizing treatment decisions for patients with PTC. However, further research and validation on larger patient cohorts are necessary to establish the robustness and generalizability of these markers in clinical practice.

show abstract

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Volpe,

Nappi,

Zampella

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Background: Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, and certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine (RAI) therapy is a cornerstone in DTC management, but cancer cells can eventually develop resistance to RAI. Radioactive iodine-refractory DTC (RAIR-DTC) is a condition defined by ATA 2015 guidelines when DTC cannot concentrate RAI ab initio or loses RAI uptake ability after the initial therapy. The RAIR condition implies that RAI cannot reveal new met-astatic foci, so RAIR-DTC metabolic imaging needs new tracers. 18F-FDG PET/CT has been widely used and has demonstrated prognostic value, but 18F-FDG DTC avidity may remain low. Fibroblast activation protein inhibitors (FA-Pi)s, prostatic-specific membrane antigen (PSMA), and somatostatin receptor (SSTR) tracers have been proposed as theragnostic agents in experimental settings and Arg-Gly-Asp (RGD) peptides in the diagnostic trial field. Multi-targeted tyrosine kinase inhibitors are relatively new drugs approved in RAIR-DTC therapy. Despite the promising targeted setting, they relate to frequent adverse-event onset. Sorafenib and trametinib have been included in re-differentiation protocols aimed at re-inducing RAI accumulation in DTC cells. Results appear promising, but not excellent. Conclusions: RAIR-DTC remains a challenging nosological entity. There are still controversies on RAIR-DTC definition and post-RAI therapy evaluation, with post-therapy whole-body scan (PT-WBS) the only validated criterion of response. The recent introduction of multiple diagnostic and therapeutic agents obliges physicians to pursue a multidisciplinary approach aiming to correct drug introduction and timing choice.

show abstract

Evaluation of integrin αvβ3-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2)

Cited by 4 publications

References 33 publications

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Contact Info

Product

Resources

About